SGP
SpyGlass Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.60
+2.50%Oct 19, 2026, 12:00 UTC
SpyGlass Pharma announced positive four-year first-in-human trial results for its BIM-IOL System, including a 37% reduction in mean intraocular pressure across dose groups, 86% of patients remaining off topical IOP-lowering drops, and 90% maintaining at least 20/25 best-corrected distance visual acuity, with no product-related adverse events reported.
Source:Oct 1, 2026, 12:00 UTC
SpyGlass Pharma acquired all outstanding shares of Advanced Vision Science, Inc. from Santen Pharmaceutical for approximately $13 million in cash.